

Michael Millward

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3230596/publications.pdf>

Version: 2024-02-01

102
papers

8,501
citations

159585

30
h-index

45317

90
g-index

105
all docs

105
docs citations

105
times ranked

10719
citing authors

#	ARTICLE	IF	CITATIONS
1	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2012, 380, 358-365.	13.7	2,691
2	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	27.0	1,572
3	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015, 386, 444-451.	13.7	1,175
4	Adjuvant nivolumab versus ipilimumab in resected stage IIIb and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 1465-1477.	10.7	330
5	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. <i>Oncotarget</i> , 2015, 6, 42008-42018.	1.8	278
6	Indwelling Pleural Catheters Reduce Inpatient Days Over Pleurodesis for Malignant Pleural Effusion. <i>Chest</i> , 2012, 142, 394-400.	0.8	140
7	Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. <i>Investigational New Drugs</i> , 2012, 30, 2303-2317.	2.6	133
8	Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. <i>Cancer Letters</i> , 2017, 404, 62-69.	7.2	98
9	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. <i>European Journal of Cancer</i> , 2018, 104, 137-144.	2.8	97
10	Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. <i>Clinical Biochemistry</i> , 2015, 48, 999-1002.	1.9	95
11	A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 118, 1035-1041.	6.4	77
12	Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. <i>BMC Cancer</i> , 2018, 18, 726.	2.6	77
13	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	2.8	71
14	An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). <i>Journal of Clinical Oncology</i> , 2013, 31, 9013-9013.	1.6	68
15	Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2040-2048.	0.7	66
16	Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. <i>Investigational New Drugs</i> , 2012, 30, 1065-1073.	2.6	60
17	Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436). <i>Clinical Cancer Research</i> , 2014, 20, 4449-4458.	7.0	56
18	PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study. <i>Oncologist</i> , 2020, 25, e520-e527.	3.7	54

#	ARTICLE	IF	CITATIONS
19	Secreted Frizzled-Related Protein 4 Inhibits Glioma Stem-Like Cells by Reversing Epithelial to Mesenchymal Transition, Inducing Apoptosis and Decreasing Cancer Stem Cell Properties. PLoS ONE, 2015, 10, e0127517.	2.5	53
20	PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. European Journal of Cancer, 2015, 51, 879-892.	2.8	53
21	Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. Journal of Translational Medicine, 2012, 10, 192.	4.4	52
22	Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. Pigment Cell and Melanoma Research, 2020, 33, 358-365.	3.3	51
23	Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer, 2014, 14, 423.	2.6	48
24	Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. European Journal of Cancer, 2020, 125, 114-120.	2.8	47
25	Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. Oncotarget, 2017, 8, 67355-67368.	1.8	45
26	Sensitive droplet digital PCR method for detection of <i>TERT</i> promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget, 2017, 8, 78890-78900.	1.8	44
27	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. Clinical Cancer Research, 2020, 26, 5926-5933.	7.0	41
28	Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. British Journal of Cancer, 2020, 122, 1059-1067.	6.4	41
29	COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF ^{V600E/K} mutation-positive cutaneous melanoma. Journal of Clinical Oncology, 2014, 32, 9011-9011.	1.6	40
30	A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision. Translational Vision Science and Technology, 2019, 8, 12.	2.2	33
31	Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cells, 2020, 9, 2393.	4.1	31
32	Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF ^{V600E} -mutated melanoma. Journal of Clinical Oncology, 2012, 30, LBA8500-LBA8500.	1.6	31
33	Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice. Pathology, 2018, 50, 389-401.	0.6	30
34	Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Cancer Discovery, 2022, 12, 1676-1689.	9.4	30
35	Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell and Melanoma Research, 2019, 32, 553-563.	3.3	28
36	A comparative study of extracellular vesicle-associated and cell-free DNA and RNA for HPV detection in oropharyngeal squamous cell carcinoma. Scientific Reports, 2020, 10, 6083.	3.3	28

#	ARTICLE	IF	CITATIONS
37	Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring. <i>Frontiers in Oncology</i> , 2013, 3, 54.	2.8	27
38	Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	3.0	27
39	A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 142, 34-40.	2.0	27
40	Patients'™ and doctors'™ preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: What makes it worthwhile?. <i>European Journal of Cancer</i> , 2015, 51, 1529-1537.	2.8	23
41	Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. <i>Oncotarget</i> , 2019, 10, 113-122.	1.8	23
42	Optimizing combination dabrafenib and trametinib therapy in BRAF mutation- positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 5-12.	1.1	22
43	Medical Oncology Group of Australia position statement and membership survey on voluntary assisted dying. <i>Internal Medicine Journal</i> , 2018, 48, 774-779.	0.8	22
44	A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2020, 140, 87-92.	2.0	21
45	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. , 2020, 8, e000410.		21
46	<p>A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 1177-1189.	4.3	21
47	Genomic Analysis of Circulating Tumor DNA-Using a Melanoma-Specific UltraSEEK Oncogene Panel. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 418-426.	2.8	18
48	Real- world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 26-30.	1.1	18
49	Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. <i>British Journal of Cancer</i> , 2022, 126, 401-408.	6.4	18
50	The effects of phenoxodiol on the cell cycle of prostate cancer cell lines. <i>Cancer Cell International</i> , 2014, 14, 110.	4.1	16
51	Clinical and therapeutic implications of <i><sc>BRAF</sc></i> mutation heterogeneity in metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 233-242.	3.3	16
52	Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles. <i>Cancers</i> , 2019, 11, 157.	3.7	16
53	Equivocal ALK fluorescence in situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing. <i>Histopathology</i> , 2015, 67, 654-663.	2.9	15
54	Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features. <i>Modern Pathology</i> , 2019, 32, 524-531.	5.5	13

#	ARTICLE	IF	CITATIONS
55	The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond BRAF Mutant Detection. <i>Cancers</i> , 2020, 12, 3793.	3.7	12
56	Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study. <i>Frontiers in Oncology</i> , 2020, 10, 1041.	2.8	12
57	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
58	Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF^{V600E}-mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA8500-LBA8500.	1.6	12
59	Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 440-451.	2.8	12
60	Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. <i>Cancers</i> , 2019, 11, 920.	3.7	10
61	Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression. <i>Cancers</i> , 2020, 12, 3486.	3.7	10
62	First-in-human phase I study of a selective c-Met inhibitor volitinib (HMP504/AZD6094) in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11111-11111.	1.6	10
63	Mutational Analysis of BRAF Inhibitor—Associated Squamoproliferative Lesions. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 644-651.	2.8	9
64	Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report. <i>BMC Cancer</i> , 2019, 19, 1109.	2.6	9
65	Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3000-3000.	1.6	9
66	A first-in-human dose phase 1 study of LY3009120 in advanced cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2507-2507.	1.6	9
67	Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in Australia. <i>Internal Medicine Journal</i> , 2017, 47, 888-893.	0.8	8
68	Prognostic Relevance of CCDC88C (Daple) Transcripts in the Peripheral Blood of Patients with Cutaneous Melanoma. <i>Scientific Reports</i> , 2018, 8, 18036.	3.3	8
69	KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9513-9513.	1.6	8
70	INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS3113-TPS3113.	1.6	8
71	Increased interdigitation zone visibility on optical coherence tomography following systemic fibroblast growth factor receptor 1 tyrosine kinase inhibitor anticancer therapy. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 579-590.	2.6	7
72	An open-label, multi-center phase I study of the safety and tolerability of the novel immunomodulatory agent PG545 in subjects with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3083-3083.	1.6	7

#	ARTICLE	IF	CITATIONS
73	Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. <i>British Journal of Cancer</i> , 2022, 126, 576-585.	6.4	7
74	Effectiveness of dabrafenib in the treatment of patients with BRAF V600E mutated metastatic melanoma in a Named Patient Program. <i>Melanoma Research</i> , 2019, 29, 527-532.	1.2	6
75	Low-coverage whole-genome sequencing of extracellular vesicle-associated DNA in patients with metastatic cancer. <i>Scientific Reports</i> , 2021, 11, 4016.	3.3	6
76	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 417-431.	4.2	6
77	Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100405.	1.7	6
78	A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17049-e17049.	1.6	6
79	An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9584-9584.	1.6	6
80	Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. <i>Oncotarget</i> , 2020, 11, 4016-4027.	1.8	6
81	Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9015-9015.	1.6	6
82	Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600E mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9526-9526.	1.6	5
83	EGFR mutation testing in NSCLC: Patterns of care and outcomes in Western Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 66-71.	1.1	4
84	Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2371-2383.	2.4	4
85	Detection of Low-level EGFR c.2369 C>T (p.Thr790Met) Resistance Mutation in Pre-treatment Non-small Cell Lung Carcinomas Harboring Activating EGFR Mutations and Correlation with Clinical Outcomes. <i>Pathology and Oncology Research</i> , 2020, 26, 2371-2379.	1.9	4
86	Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9050-9050.	1.6	4
87	Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9513-9513.	1.6	4
88	Dynamic Landscape of Extracellular Vesicle-Associated Proteins Is Related to Treatment Response of Patients with Metastatic Breast Cancer. <i>Membranes</i> , 2021, 11, 880.	3.0	4
89	Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 102-102.	1.6	3
90	A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3066-3066.	1.6	3

#	ARTICLE	IF	CITATIONS
91	Clinical Trial of NPI-0052 (2nd generation proteasome inhibitor) in Patients Having Advanced Malignancies with Expanded RP2D Cohorts in Lymphoma and CLL. <i>Blood</i> , 2008, 112, 4934-4934.	1.4	2
92	Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052.. <i>Blood</i> , 2009, 114, 2693-2693.	1.4	2
93	Oncologists' estimates of expected survival time and scenarios for survival: accuracy in the ALTC NITRO trial of 1st line chemotherapy for advanced non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9074-9074.	1.6	2
94	Reply to "Comment on "Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy". <i>British Journal of Cancer</i> , 2017, 116, e15-e15.	6.4	1
95	A phase 1b study of the anticancer stem cell agent demcizumab (DEM), pemetrexed (PEM), and carboplatin (CARBO) in pts with first-line nonsquamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2544-2544.	1.6	1
96	FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS42-TPS42.	1.6	1
97	A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2688-TPS2688.	1.6	1
98	Patient human leukocyte antigen (HLA) genotype may predict response to anti-programmed death receptor 1 (anti-PD1) in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21512-e21512.	1.6	0
99	Phase II trial of BNC105P as second-line chemotherapy for advanced malignant pleural mesothelioma (MPM): Australasian Lung Cancer Trials Group and NHMRC Clinical Trials Centre Collaboration.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7079-7079.	1.6	0
100	Assessment of tissue and blood tumor mutational burden in patients with melanoma using a 523-gene clinical assay.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21570-e21570.	1.6	0
101	Autoantibodies as potential biomarkers of immune-related adverse events in patients with advanced cutaneous melanoma treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9536-9536.	1.6	0
102	A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3105-3105.	1.6	0